Cover Image

The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial

Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the six-month effect of infliximab or vedolizumab vs. no biolog...

Full description

Saved in:

Bibliographic Details
Main Authors:	Apostolis Papaefthymiou (Author), Styliani Sarrou (Author), Konstantinos Pateras (Author), Ilias D. Vachliotis (Author), Georgios Agrotis (Author), Ioanna-Konstantina Sgantzou (Author), Georgios Perifanos (Author), Andreas Kapsoritakis (Author), Matthaios Speletas (Author), Marianna Vlychou (Author), George N. Dalekos (Author), Spyros Potamianos (Author), Antonis Goulas (Author), Jannis Kountouras (Author), Stergios A. Polyzos (Author)
Format:	Book
Published:	MDPI AG, 2024-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
by: Michael Doulberis, et al.
Published: (2020)

An association study of the PNPLA3 I148M polymorphism (rs738409) with serum lipids in patients with dyslipidemia
by: Despoina Ioannidou, et al.
Published: (2023)

Common variable immune deficiency with mutated TNFSRF13B gene presenting with autoimmune hematologic manifestations
by: Elpis Mantadakis, et al.
Published: (2016)

Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation
by: Matthaios Speletas, et al.
Published: (2011)

Impact of Gamification on Students' Learning Outcomes and Academic Performance: A Longitudinal Study Comparing Online, Traditional, and Gamified Learning
by: Georgios Lampropoulos, et al.
Published: (2024)

The Potential Impact of the Gut Microbiota on Neonatal Brain Development and Adverse Health Outcomes
by: Maria Tzitiridou-Chatzopoulou, et al.
Published: (2024)

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Emidio Scarpellini, et al.
Published: (2024)

Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases
by: Sotiris Anastasiadis, et al.
Published: (2018)

Iron, Oxidative Stress, and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Sophie Gensluckner, et al.
Published: (2024)

Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice
by: Gi Cheol Park, et al.
Published: (2024)

Steatotic liver disease and diabetes: prolific nomenclature, insufficient data, and poor treatment options
by: The Lancet Regional Health - Americas
Published: (2024)

Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
by: Jiaxin Chen, et al.
Published: (2024)

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
by: Yumin Wang, et al.
Published: (2024)

Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions
by: Elisa Balboa, et al.
Published: (2024)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
by: Baoqiang Zhu, et al.
Published: (2023)

Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives
by: Torre E, et al.
Published: (2024)

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
by: Myung Jin Kim, et al.
Published: (2024)

Correlation Between Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Urinary Incontinence in Adult Women
by: Zhang F, et al.
Published: (2024)

Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission
by: Xiuli Lin, et al.
Published: (2024)

Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions
by: Xiaoxiao Li, et al.
Published: (2024)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
by: Adrian Kruszewski, et al.
Published: (2024)

A Comparative Analysis of Symmetry Indices for Spatiotemporal Gait Features in Early Parkinson's Disease
by: Erasmia Giannakou, et al.
Published: (2023)

Association between life's essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults
by: Zheng Wang, et al.
Published: (2024)

Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD: Jordan’s Perspective Based on Knowledge and Attitude Determinants
by: Alqudah O, et al.
Published: (2024)

Myokines and Their Potential Protective Role Against Oxidative Stress in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: José Luis Bucarey, et al.
Published: (2024)

Exploratory Role of Flavonoids on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a South Italian Cohort
by: Caterina Bonfiglio, et al.
Published: (2024)

Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
by: Antonella Mosca, et al.
Published: (2024)

Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions
by: O.E. Abaturov, et al.
Published: (2024)

Gastric Carcinoma with Osteoclast-Like Giant Cells Coexisting with Gastrointestinal Spindle Cell Tumor
by: Christos Poulios, et al.
Published: (2013)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
by: Yanrui Wu, et al.
Published: (2023)

Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey
by: Jing Zhou, et al.
Published: (2024)

PARADOXICAL ASSOCIATION OF LOW LIPOPROTEIN (A) WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE SEVERITY: FINDINGS FROM THE UK BIOBANK
by: Terence B Lee, MD
Published: (2024)

Occupational stress trajectories and metabolic dysfunction-associated steatotic liver disease among female nurses: a prospective Cohort Study
by: Hanxiao Luo, et al.
Published: (2024)

Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease
by: Wei-Chun Cheng, et al.
Published: (2024)

Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia
by: Karli R. LeFort, et al.
Published: (2023)

Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges
by: Ying Yang, et al.
Published: (2024)

Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity
by: Huanyu Wang, et al.
Published: (2024)

The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Li N, et al.
Published: (2024)

Comparing diabetes prediction based on metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease: the ELSA-Brasil study
by: Gabriela Wünsch Lopes, et al.
Published: (2024)

Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease
by: Hye Young Jin, et al.
Published: (2024)